PAR-21-340: Limited Competition: High Impact Specialized Innovation Programs in Clinical and Translational Science for UM1 CTSA Hub Awards (RC2 Clinical Trials Not Allowed)
Closed
This grant is closed. Who won this program's grants before is below, and similar open grants are at the end of the page. It is in our archive of National Institutes of Health notices from 2021.
National Institutes of Health offered grants of up to $500,000 to colleges and universities. Applications closed on November 7, 2023.
From the official notice on Grants.gov, last changed November 7, 2023. Checked November 7, 2026.
- Award ceiling$500,000
- Cost sharingNot required
- Funding typeGrant
About this NIH notice
- Activity codeRC2
- Clinical trialsNot allowed
- Funded byNCATS
- Median yearly award$769,998
- Typical project length5 years
Projects funded under PAR-21-340 were run by National Center for Advancing Translational Sciences (NCATS, 5 projects). Contact the program officer at the institute that fits your project before you apply; the notice lists them.
Application due dates, page limits and budget limits are set in the notice. Read PAR-21-340 in the NIH Guide.
Key dates
| Posted | September 17, 2021 |
|---|---|
| Deadline | November 7, 2023 |
| Archived by Grants.gov | December 7, 2023 |
Who can apply
This opportunity was open to colleges and universities.
- Public and State controlled institutions of higher education
Other Eligible Applicants include the following: Non-domestic (non-U.S.) Entities (Foreign Institutions) are not eligible to apply. Non-domestic (non-U.S.) components of U.S. Organizations are not eligible to apply. Foreign components, as defined in the NIH Grants Policy Statement, are allowed. See the Funding Announcement for Full Eligibility Details
Is this a realistic fit?
- Projects NIH funded under this notice had a median yearly award of $769,998; it allows up to $500,000 per award.
- Most of the program's money (82% over five years) went to colleges and universities.
- No cost sharing or match is required.
What the grant funds
The purpose of the High Impact Specialized Innovation Programs (SIPs) is to support the development and demonstration of unique hub capabilities, research platforms and/or resources to address in a timely manner critical gap areas and/or roadblocks in clinical and translational science at awarded UM1 Clinical and Translational Science Awards (CTSA) Program Hubs (PAR-21-293). Successful programs supported through this funding opportunity are expected to lay a strong foundation for future adoption and/or dissemination of capabilities to additional CTSA Program Hubs.
Funded under PAR-21-340 so far
NIH funded 5 projects under PAR-21-340 in fiscal 2023 to 2026, at 5 institutions. The median yearly award was $769,998.
| Project | Institution | Fiscal year | Award |
|---|---|---|---|
| Virginia Accountable Health Engagement and Action Dashboard: Community Framing of Health Data to Support Clinical Translational Science | Virginia Commonwealth University | 2026 | $2.1 million |
| CTSA RC2 Program at University of Utah: A Translational Platform for Rapid Genomic Medicine | Utah State Higher Education System--University of Utah | 2026 | $769,954 |
| Optimizing integration of veterinary clinical research findings with human health systems to improve strategies for early detection and intervention | Tufts University Boston | 2026 | $811,280 |
| Center for Virtual Care Value and Excellence (ViVE). | Univ of North Carolina Chapel Hill | 2026 | $742,275 |
| Clinical and Translational Science Collaborative of Northern Ohio, Systems Marketing Analysis for Research Translation (SMART) Innovation Program | Case Western Reserve University | 2026 | $1.4 million |
Who has won National Center for Advancing Translational Sciences grants before
From fiscal 2021 to 2025, National Center for Advancing Translational Sciences (93.350) awarded $3.1 billion across 867 grant awards, an average of $3.6 million per award.
| Recipient | State | Awards | Amount |
|---|---|---|---|
| University of Pittsburgh - of the Commonwealth System of Higher Education | Pennsylvania | 15 | $95.3 million |
| Vanderbilt University Medical Center | Tennessee | 10 | $94.6 million |
| Duke University | North Carolina | 11 | $88.9 million |
| University of North Carolina at Chapel Hill | North Carolina | 16 | $74.5 million |
| The Johns Hopkins University | Maryland | 20 | $70.7 million |
Applying now
This notice no longer takes applications. Agencies often post the same opportunity again under a new number, so check the program's notices on Grants.gov and the similar open grants below.
The notice on Grants.gov keeps its full text and attachments, which is useful for planning a resubmission.
Questions people ask
Is PAR-21-340 still open?
No. It closed on November 7, 2023.
Who can apply for Limited Competition: High Impact Specialized Innovation Programs in Clinical and Translational Science for UM1 CTSA Hub Awards (RC2 Clinical Trials Not Allowed)?
National Institutes of Health accepted applications from colleges and universities. The notice adds further conditions, so read its eligibility section.
What is the deadline for Limited Competition: High Impact Specialized Innovation Programs in Clinical and Translational Science for UM1 CTSA Hub Awards (RC2 Clinical Trials Not Allowed)?
Closed November 7, 2023. Applications are no longer accepted; the program's newer notices are on this page when there are any.
How much funding is available?
Awards of up to $500,000 each.
Who has been funded under PAR-21-340?
NIH RePORTER lists 5 projects funded under PAR-21-340 in fiscal 2023 to 2026, at 5 institutions. The most were at Virginia Commonwealth University, Utah State Higher Education System--University of Utah, Tufts University Boston.
Who has won National Center for Advancing Translational Sciences grants before?
The largest recipients over five fiscal years were University of Pittsburgh - of the Commonwealth System of Higher Education, Vanderbilt University Medical Center, Duke University. The program made 867 awards worth $3.1 billion in that time.
Similar open grants
- Change of Recipient Organization (Type 7 Parent Clinical Trial Optional)
- Data Coordinating Center for the Aging and Alzheimer’s Disease Mouse Brain Atlas (AD-MBA) (U24 Clinical Trial Not Allowed)
- Amyotrophic Lateral Sclerosis (ALS) Intermediate Patient Population Expanded Access (U01 Clinical Trial Required)
- Advanced Development and Validation of Emerging Technologies for Basic and Clinical Cancer Research (R33 Clinical Trial Not Allowed)
- Early-Stage Innovative Technology Development for Basic and Clinical Cancer Research (R61 Clinical Trial Not Allowed)
- Infectious Diseases Clinical Trials Network (IDCTN) (UM1 Clinical Trial Required)